"Sucrose" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonreducing disaccharide composed of GLUCOSE and FRUCTOSE linked via their anomeric carbons. It is obtained commercially from SUGARCANE, sugar beet (BETA VULGARIS), and other plants and used extensively as a food and a sweetener.
| Descriptor ID |
D013395
|
| MeSH Number(s) |
D09.698.629.305.770 D09.947.750.770
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sucrose".
Below are MeSH descriptors whose meaning is more specific than "Sucrose".
This graph shows the total number of publications written about "Sucrose" by people in this website by year, and whether "Sucrose" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 2 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 3 | 0 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sucrose" by people in Profiles.
-
Chronic Fructose and Sucrose Intake and 24-Hour Urine Composition. Kidney360. 2024 Aug 01; 5(8):1167-1177.
-
Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis. Am J Nephrol. 2024; 55(2):127-135.
-
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. J Nephrol. 2022 04; 35(3):875-888.
-
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf. 2021 Dec; 20(12):1463-1472.
-
Computational Characterization of Antibody-Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach. Mol Pharm. 2020 11 02; 17(11):4323-4333.
-
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
-
Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. Nephrol Dial Transplant. 2020 06 01; 35(6):946-954.
-
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 07 01; 34(7):1163-1170.
-
High-Throughput Single-Cell Transcriptome Profiling of Plant Cell Types. Cell Rep. 2019 05 14; 27(7):2241-2247.e4.
-
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148.